Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, Jane L. Liesveld, Deborah A. Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Paul M. Barr

Blood Adv (2024) 8 (2): 378–387.

https://doi.org/10.1182/bloodadvances.2023010693

Published: 2024

Journal Articles

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr

Blood Adv (2023) 7 (11): 2496–2503.

https://doi.org/10.1182/bloodadvances.2022009382

Published: 2023

Includes: Supplemental data

Journal Articles

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes

Marissa LoCastro, Andrea M. Baran, Jane L. Liesveld, Eric Huselton, Michael W. Becker, Kristen Marie O’Dwyer, Omar S. Aljitawi, Megan Baumgart, Eric Snyder, Benzi Kluger, Kah Poh Loh, Jason H. Mendler

Blood Adv (2021) 5 (24): 5554–5564.

https://doi.org/10.1182/bloodadvances.2021004775

Published: 2021